Related Experiment Video

Updated: May 24, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Genetic copy number variants in myocardial infarction patients with hyperlipidemia

Wei-Chung Shia1, Tien-Hsiung Ku, Yu-Ming Tsao

  • 1Department of Information Engineering and Computer Science, Feng Chia University, Taichung City, Taiwan.

BMC Genomics
|February 29, 2012
PubMed

Insights

Copy number variations (CNVs) were found to be significantly associated with hyperlipidemia and myocardial infarction (MI). These identified CNV regions may serve as potential biomarkers for early diagnosis of cardiovascular disease.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Biomarker Discovery

Background:

  • Cardiovascular disease, particularly myocardial infarction (MI), is a leading cause of death globally.
  • Hyperlipidemia is a significant risk factor for MI, contributing to atherosclerosis.
  • Copy number variation (CNV) analysis is increasingly used in genomewide association studies for complex diseases.

Purpose of the Study:

  • To investigate the association between copy number variations (CNVs) and hyperlipidemia in patients with myocardial infarction (MI).
  • To identify potential genetic biomarkers for early diagnosis of cardiovascular disease.

Main Methods:

  • Analysis of CNVs in blood samples from 31 patients with hyperlipidemia and MI using SNP arrays.
  • Multistage analysis to identify significantly associated CNV regions.
  • Validation of a specific CNV region (10q11.21) using quantitative real-time PCR.

Main Results:

  • Seven CNV regions were significantly associated with hyperlipidemia and MI (P<0.001).
  • Notable regions include 1p21.3, 1q31.2 (CDC73), 1q42.2 (DISC1), 3p21.31 (CDCP1), 10q11.21 (RET), 12p12.3 (PIK3C2G), and 16q23.3 (CDH13).
  • Quantitative real-time PCR results confirmed the microarray findings for the 10q11.21 region.

Conclusions:

  • Preliminary findings suggest CNV regions are associated with hyperlipidemia and MI.
  • Identified susceptibility CNV regions offer a novel approach for evaluating cardiovascular disease risk.
  • These CNV regions hold potential as biomarkers for the early diagnosis of hyperlipidemia and MI.
Abstract

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...